- $706.91m
- $1.12bn
- $1.06bn
U.S. RESEARCH ROUNDUP-Arrivent Biopharma, Ferguson, Target
Brief: Enhabit Q3 adjusted EPS USD 0.03 vs. IBES estimate USD 0.06
Enhabit Inc expected to post earnings of 6 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Adobe, Matador Resources, ServiceNow
Brief: Arex Capital Issues Letter To Board Of Enhabit, Inc.
U.S. RESEARCH ROUNDUP-B&G Foods, General Motors Co, Point Biopharma Global
Brief: Enhabit Home Health & Hospice Confirms Exploration Of Strategic Alternatives
Brief: Arex Capital Management - Requests Board Refreshment At Enhabit
U.S. RESEARCH ROUNDUP-Caci International, Cyberark Software, Ralph Lauren
Enhabit Inc reports results for the quarter ended in June - Earnings Summary
Brief: Enhabit Q2 adjusted EPS USD 0.04
Enhabit Inc expected to post earnings of 14 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Huntington Bancshares, Kodiak Sciences, Prokidney
U.S. STOCKS ON THE MOVE-Rio Tinto, BurgerFi International, Aclaris Therapeutics
U.S. STOCKS ON THE MOVE-Comerica, copper miners, Journey Medical
Enhabit up after Arex Capital pushes company to consider sale
Brief: Arex Capital Management Seeks Commitment From Enhabit To Launch Review Of Strategic Alternatives Before 2023-End
Arex Capital pushes Enhabit to consider company sale - letter
Brief: Enhabit Reports First Quarter 2023 Financial Results And Reaffirms Full-Year Guidance